IL2RG
Cytokine receptor common subunit gamma
As of the edition of 20 October 2026, IL2RG (cytokine receptor common subunit gamma, UniProt P31785) has 6 drugs tested at it and 7 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P31785
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 14
- Disease areas
- Cancer; Immune system; Blood and lymph; Lungs and airways; Infections; Urinary and reproductive; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 39
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nogapendekin alfa inbakicept | Marketed | Phase 3 | Ends 2036 |
| Pegenzileukin | Active | Phase 2 | none listed |
| Simlukafusp alfa | Active | Phase 3 | none listed |
| BIIB019 | Went quiet | Phase 3 | none listed |
| REGN7257 | Stopped | Phase 1 | none listed |
| Teceleukin | Marketed | No phase stated | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Undetermined | 4 |
| Total on the list | 7 |
The other 4 companies at IL2RG
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at IL2RG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.